COVID-19 Infection | Norton Healthcare

Indication: COVID-19 Infection

A Phase 2, Open label Randomized Study of the Efficacy and Safety of Acalabrutinib (a BTK inhibitor) with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19

Sub-indication: COVID-19 Infection

Study Type: Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Sponsor: AstraZeneca

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.